Several in vivo studies with HO-1-deficiency have demonstrated a cytoprotective effect of HO-1 in human diseases including systemic inflammation, hemolysis, nephritis, asplenia, nephropathy, and vascular endothelial injury [9,10]. This evidence concerns the gene HMOX1 and hemolysis.